Photo of Professor Peter Kuhn

University Professor of Biological Sciences, Medicine, Biomedical Engineering, Aerospace & Mechanical Engineering, and Urology.

Peter Kuhn is a scientist and entrepreneur with a career long commitment in personalized medicine and individualized patient care. He is focused on the redesign of cancer care. Kuhn’s research team in physics oncology has discovered new ways of how cancer spreads to the human body and is using those breakthroughs to impact patient care.

Dr. Kuhn is the University Professor of Biological Sciences, Medicine, Biomedical Engineering, Aerospace & Mechanical Engineering and Urology in the USC Dornsife College of Letters, Arts and Sciences. He is a founding member of the Michelson Center for Convergent Biosciences, a co-founder of the USC Michelson Center for Convergent Bioscience Bridge Institute and director of the Convergent Science Institute in Cancer (CSI-Cancer). Dr. Kuhn’s strategy is to advance our understanding of the human body to improve the human condition. His research is shedding new light at how cancer spreads through the body. This new science will lead to a personalized care strategy that is biologically informed and clinically actionable.

Dr. Kuhn is a physicist who trained initially at the Julius Maximilians Universität Würzburg, Germany, before receiving his Masters in Physics at the University of Albany, Albany, NY in 1993 and his Ph.D. in 1995. He then moved to Stanford University where he later joined the faculties of Medicine and Accelerator Physics. From 2002 to 2014, he established a translational science program at The Scripps Research Institute in La Jolla, CA bringing together over forty scientists from basic, engineering and medical sciences to work on understanding the spread of cancer in the human body. He has published over 200 peer-reviewed scientific articles and patents as a result of his research. He founded Epic Sciences, Inc. in 2009 to develop cancer diagnostic products. Today Epic Sciences is a premier partner to most pharmaceutical and biotech companies in the development of precision companion diagnostics for cancer care.

More information about Peter Kuhn’s research.